Nasdaq’s Sonnet to Merge With Rorschach, Form $888 Million Crypto Treasury Firm

Sonnet BioTherapeutics, a Nasdaq-listed clinical-stage biotechnology company, said it will merge with Rorschach I LLC in an all-stock deal that values the combined business at about $888 million

Loading this article…